OncoHost business update

Hi Josb,

We are pleased to share with you a business update about OncoHost. The first closing of the current investment round in the amount of $22M will be completed on Thursday April 14th, with the participation of Alive VC, Partam HighTech, and OurCrowd. We were able to secure an additional allocation of up to $3M and the possibility to participate in a deferred closing at the end of June.

Since this investment opportunity was launched, OncoHost reports the following progress. The details in this email are based on information received from, and verified solely by, the company.

BOOK A CALL
with your Investor Relations representative

Business Update:

Alive VC, the lead investor in this round, will invest $20M together with Menora Mivtachim, and Leumi partners.
OncoHost's lab received its CLIA registration earlier than expected. This is another significant step toward the commercialization planned for the beginning of Q3 2022.
OncoHost onboarded its first US employees including a Clinical Director and Lab Supervisor. In May, Daniel Delubac will join the company as OncoHost's new US President. He was previously the COO of a diagnostics services unicorn in the US.
OncoHost increased its clinical footprint with Roswell Park Comprehensive Cancer Center in Buffalo, NY, joining its multi-center clinical trial.

Investment Summary

Qualitative Description of Round: Series C Financing

See the deal terms here for further details.

Reserve Your Spot

If you would like to secure an allocation in this round, please click here or be in touch with your Investor Relations representative to confirm your allocation.

Certain information in this email contains "forward-looking information" under applicable securities laws ("forward-looking statements"). These may include, among others, projected performance; expected development of the company's business, projects and partnerships; execution of the company's vision and growth strategy; and the like. Forward-looking statements are not guarantees of future performance and should not be relied on in any way.

Nothing contained in and accompanying this communication shall be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security by OurCrowd, its portfolio companies or any third party. Information regarding OurCrowd's limited partnerships and/or portfolio companies and the investment opportunities on OurCrowd's website is intended and available for accredited investors only (criteria at OurCrowd). OurCrowd urges potential investors to consult with licensed legal professionals and investment advisors for any legal, tax, insurance, or investment advice.OurCrowd operates in Canada through OurCrowd Canada Inc., an exempt market dealer registered in the Provinces of British Columbia, Alberta, Manitoba, Ontario, Quebec and Nova Scotia.